Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy: a Multicenter Randomized Controlled Trial

NCT06078839 is registered in ClinicalTrials.gov with Xu Li as lead sponsor.

NCT NCT06078839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06078839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy: a Multicenter Randomized Controlled Trial
Lead sponsor
Xu Li
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 1, 2023
Completion date
October 1, 2026
Enrollment
778 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nafamostat mesilate, sepsis, sepsis-induced coagulopathy